BERKELEY HEIGHTS, NJ, September 21, 2022 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. CYCCCYCCP “, Cyclacel” or the “, Company”, ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that management will be present at the Ladenburg Thalmann Healthcare Conference 2022 on September 29, 2022 at the Sofitel New York will participate.
| Incident: | Ladenburg Thalmann Health Congress 2022 |
| Date: | Thursday, 09/29/2022 |
| Time/Place: | 9:30 a.m. ET, Platform 2, St. Germain III |
| Format: | Fireside chat presentation |
| web cast: | shortcut |
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage biopharmaceutical company developing innovative anticancer drugs based on cell cycle, transcriptional regulation and mitotic biology. The transcription regulation program is evaluating Fadraciclib, a CDK2/9 inhibitor, and the antimitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates in oncology and hematology indications. For more information, see www.cyclacel.com.
contacts
© Copyright 2022 Cyclacel Pharmaceuticals, Inc. All rights reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
